DSMによるケンセイ・ナッシュの公開買付けが成立、買収は数日以内に完了の見込み

Heerlen, NL, 19 Jun 2012 09:15 CEST

ライフサイエンスとマテリアルサイエンスのグローバルカンパニーであるRoyal DSM (NYSE Euronext: DSM KON)は本日、ケンセイ・ナッシュ・コーポレーション（NASDAQ: KNSY）の発行済普通株式を1株当たり38.50ドルで買い取る公開買付けが成立したと発表した。

本公開買付けは 2012 年 6 月 18 日（月）午前 0 時（ニューヨーク市時間）に終了し、公開買付代理人によれば、公開買付けに応募され、かつ応募が撤回されなかったケンセイ・ナッシュの普通株式は 7,151,081 株（276,900 株を含む）であり、ケンセイ・ナッシュの現在の発行済株式総数の約 82％（交付保証による応募を除くと約 79％）に相当するとのことです。 DSM は有効な応募株式をすべて受付けました。

As part of the merger agreement, Kensey Nash granted to DSM an irrevocable option (the “top-up option”) to purchase the number of authorized but unissued shares of Kensey Nash common stock that, when added to the number of shares owned by DSM immediately prior to exercise of the top-up option, constitutes one share more than 90% of the number of shares then outstanding. DSM plans to exercise the top-up option and to complete a short-form merger in accordance with the merger agreement within the next few days. In the short-form merger, Biomedical Acquisition Corporation will merge with and into Kensey Nash and each share of Kensey Nash common stock not tendered in the tender offer, other than those as to which holders exercise appraisal rights under Delaware law and those held by DSM or Kensey Nash or their respective wholly-owned subsidiaries, will be converted in the merger into the right to receive $38.50 per share in cash, without interest and less any required withholding taxes. This is the same price

ケンセイ・ナッシュ

ケンセイ・ナッシュは、独自のコラーゲンと合成ポリマー技術を活用した再生医療に主眼を置く医療機器メーカーであり、再吸収性生体材料の分野における革新的な製品開発と独自の技術でリーダー的存在として認められている。 同社は広範な製品群を有し、戦略的パートナーを通じて、心臓病、整形外科、スポーツ医学、脊椎、外傷、頭蓋顎顔面、一般外科などの複数の医療市場で販売されている。

 This news release and the description contained herein is neither an offer to purchase nor a solicitation of an offer to sell shares of Kensey Nash. On 21 May 2012, DSM and its wholly-owned subsidiary, Biomedical Acquisition Corporation, filed a Tender Offer Statement on Schedule TO containing an offer to purchase, a form of letter of transmittal and other documents relating to the tender offer and Kensey Nash filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. DSM, Biomedical Acquisition Corporation and Kensey Nash mailed these documents to the stockholders of Kensey Nash. These documents contain important information about the tender offer and stockholders of Kensey Nash are urged to read them carefully. Stockholders of Kensey Nash can obtain a free copy of these documents and other documents filed by Kensey Nash, DSM or Biomedical Acquisition Corporation with the Securities and Exchange Commission at the website maintained by the SEC at xml-ph-0000@deepl.intern